DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

by Patrick J. Engelberts, Ida H. Hiemstra, Bart de Jong, Danita H. Schuurhuis, Joyce Meesters, Irati Beltran Hernandez, Simone C. Oostindie, Joost Neijssen, Edward N. van den Brink, G. Jean Horbach, Sandra Verploegen, Aran F. Labrijn, Theodora Salcedo, Janine Schuurman, Paul W.H.I Parren, Esther C.W. Breij
Published 2020-02-01